Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX Trial): A randomized clinical trial

JAMA Ophthalmology

Volumn 132, Issue 7, 2014, Pages 866-873

  Hoffman, Dennis R ^a,b   Hughbanks Wheaton, Dianna K ^a,b   Pearson, N Shirlene ^c   Fish, Gary E ^d   Spencer, Rand ^d   Takacs, Alison ^a   Klein, Martin ^a   Locke, Kirsten G ^a   Birch, David G ^a,b  

^a RETINA FOUNDATION OF THE SOUTHWEST   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c Pearson Statistical Consulting and Expert Witness Testimony   (United States)

^d TEXAS RETINA ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; PLACEBO;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; ELECTRORETINOGRAPHY; ERYTHROCYTE COUNT; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS PIGMENTOSA; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; X LINKED RETINITIS PIGMENTOSA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CAPSULES; CHILD; CHROMATOGRAPHY, GAS; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; ELECTRORETINOGRAPHY; ERYTHROCYTE MEMBRANE; GENETIC DISEASES, X-LINKED; HUMANS; MALE; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL ROD PHOTORECEPTOR CELLS; RETINITIS PIGMENTOSA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904162810     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.1634     Document Type: Article

References (40)

1. Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. Am J Ophthalmol. 1984;97(3):357-365. (Pubitemid 14160551)
2. Wheaton DH, Daiger SP, Birch DG. The Southwest Eye Registry: distribution of disease types and mutations. In: Anderson RA, LaVail M, Hollyfield JG, eds. New Insights Into Retinal Degenerative Diseases. New York, NY: Klewer-Plenum; 2001:339-345.
3. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Dryja TP. Ocular findings in patients with autosomal dominant retinitis pigmentosa and rhodopsin, proline-347-leucine. Am J Ophthalmol. 1991;111(5):614-623.
4. Ayuso C, Trujillo MJ, Robledo M, et al. Novel rhodopsin mutation in an autosomal dominant retinitis pigmentosa family: phenotypic variation in both heterozygote and homozygote Val137Met mutant patients. Hum Genet. 1996;98(1):51-54. (Pubitemid 26181281)
5. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22(2):79-131.
6. 3H- docosahexaenoyl]phosphatidate to rhodopsin during in vivo labeling of frog retinal rod outer segments. Neurochem Res. 2000;25(5):695-703.
7. Dratz EA, Deese AJ. The role of docosahexaenoic acid (22:6 ω-3) in biological membranes: examples from photoreceptors and model membrane bilayers. In: Simopoulos AP, Kifer RR, Martin RE, eds. Health Effects of Polyunsaturated Fatty Acids in Seafoods. New York, NY: Academy Press; 1986:319-351.
8. Rotstein NP, Aveldaño MI, Barrantes FJ, Politi LE. Docosahexaenoic acid is required for the survival of rat retinal photoreceptors in vitro. J Neurochem. 1996;66(5):1851-1859. (Pubitemid 26118772)
9. Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr. 2011;31(8):321-351.
10. Rojas CV, Martínez JI, Flores I, Hoffman DR, Uauy R. Gene expression analysis in human fetal retinal explants treated with docosahexaenoic acid. Invest Ophthalmol Vis Sci. 2003;44(7):3170-3177. (Pubitemid 36759789)
11. Gong J, Rosner B, Rees DG, Berson EL, Weigel-DiFranco CA, Schaefer EJ. Plasma docosahexaenoic acid levels in various genetic forms of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1992;33(9):2596-2602.
12. Hoffman DR, Birch DG. Docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1995;36(6):1009-1018.
13. Sarkadi-Nagy E, Wijendran V, Diau GY, et al. The influence of prematurity and long chain polyunsaturate supplementation in 4-week adjusted age baboon neonate brain and related tissues. Pediatr Res. 2003;54(2):244-252. (Pubitemid 36918160)
14. Hoffman DR, Birch DG. Omega 3 fatty acid status in patients with retinitis pigmentosa. World Rev Nutr Diet. 1998;83:52-60. (Pubitemid 128081431)
15. Birch DG, Birch EE, Hoffman DR, Uauy RD. Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. Invest Ophthalmol Vis Sci. 1992;33(8):2365-2376.
16. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111(6):761-772. (Pubitemid 23170587)
17. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122(9):1297-1305. (Pubitemid 39180849)
18. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004;122(9):1306-1314. (Pubitemid 39180850)
19. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol. 2004;137(4):704-718. (Pubitemid 38446685)
20. Wheaton DH, Hoffman DR, Locke KG, Watkins RB, Birch DG. Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. Arch Ophthalmol. 2003;121(9):1269-1278. (Pubitemid 37128404)
21. Marmor MF, Holder GE, Seeliger MW, Yamamoto S; International Society for Clinical Electrophysiology of Vision. Standard for clinical electroretinography (2004 update). Doc Ophthalmol. 2004;108(2):107-114. (Pubitemid 39140118)
22. Alexander KR, Raghuram A, McAnany JJ. Comparison of spectral measures of period doubling in the cone flicker electroretinogram. Doc Ophthalmol. 2008;117(3):197-203.
23. Hoffman DR, Birch EE, Birch DG, et al. Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. J Pediatr Gastroenterol Nutr. 2000;31(5):540-553.
24. Division of AIDS, National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0, December 2004; clarification August 2009. http://rsc.tech-res.com/Document/ safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric- Adverse-Events.pdf. Accessed April 3, 2014.
25. Churchill JD, Bowne SJ, Sullivan LS, et al. Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5%of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013;54(2):1411-1416.
26. Fahim AT, Bowne SJ, Sullivan LS, et al. Polymorphic variation of RPGRIP1L and IQCB1 as modifiers of X-linked retinitis pigmentosa caused by mutations in RPGR. Adv Exp Med Biol. 2012;723:313-320.
27. Rosner B. Fundamentals of Biostatistics. 3rd ed. Boston, MA: Duxbury Press; 1990:419-430.
28. Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy. Ophthalmology. 1999; 106(2):258-268. (Pubitemid 30191621)
29. Vervoort R, Lennon A, Bird AC, et al. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat Genet. 2000;25(4):462-466. (Pubitemid 32983444)
30. Breuer DK, Yashar BM, Filippova E, et al. A comprehensive mutation analysis of RP2 and RPGR in a North American cohort of families with X-linked retinitis pigmentosa. Am J Hum Genet. 2002;70(6):1545-1554. (Pubitemid 34533901)
31. Sandberg MA, Rosner B, Weigel-DiFranco C, Dryja TP, Berson EL. Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations. Invest Ophthalmol Vis Sci. 2007;48(3):1298-1304. (Pubitemid 351261427)
32. Brenna JT, Varamini B, Jensen RG, Diersen-Schade DA, Boettcher JA, Arterburn LM. Docosahexaenoic and arachidonic acid concentrations in human breastmilk worldwide. Am J Clin Nutr. 2007;85(6):1457-1464. (Pubitemid 46890412)
33. Hoffman DR, Theuer RC, Castañeda YS, et al. Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHA-enriched egg yolk. J Nutr. 2004;134(9):2307-2313. (Pubitemid 39201601)
34. Lapillonne A, Groh-Wargo S, Gonzalez CHL, Uauy R. Lipid needs of preterm infants: updated recommendations. J Pediatr. 2013;162(3)(suppl):S37-S47.
35. Lloyd-Still JD, Powers CA, Hoffman DR, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition. 2006;22(1):36-46. (Pubitemid 43175783)
36. Paker AM, Sunness JS, Brereton NH, et al. Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology. 2010;75(9):826-830.
37. Gillingham MB, Weleber RG, Neuringer M, et al. Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency. Mol Genet Metab. 2005;86(1-2):124-133. (Pubitemid 41412168)
38. Noguer MT, Martinez M. Visual follow-up in peroxisomal-disorder patients treated with docosahexaenoic acid ethyl ester. Invest Ophthalmol Vis Sci. 2010;51(4):2277-2285.
39. Querques G, Benlian P, Chanu B, et al. DHA supplementation for late onset Stargardt disease: NAT-3 study. Clin Ophthalmol. 2010;4:575-580.
40. Lee TK, Clandinin MT, Hébert M, MacDonald IM. Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial. Can J Ophthalmol. 2010; 45(5):514-519.